Abstract
Sixteen patients with recurrent childhood brain tumors were treated with intravenous cisplatin, cytosine arabinoside and etoposide (PAE), daily for three days every three to four weeks. Objective responses were observed in 6 of 15 evaluable patients and an additional six patients had stable disease for > 6 months. The tumor-specific response rate for astrocytoma/glioma was 3 of 7 and for medulloblastoma was 2 of 4. The mean progression-free interval was 11.0 months and the hazard rate for progression was 0.085 per patient-month of observation. The most common toxicities were neutropenia and thrombocytopenia. Clinically significant ototoxicity wasidentified in 7 patients. The activity of PAE chemotherapy for recurrent childhood brain tumors warrants further investigation.
Similar content being viewed by others
References
Khan AB, D'Souza BJ, Wharam MD, et al.: Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 66: 2013–2020, 1982
Sexauer CL, Khan A, Burger PC, et al.: Cisplatin in recurrent pediatric brain tumors. A POG phase II study. A Pediatric Oncology Group study. Cancer 56: 1497–1501, 1985
Walker RW, Allen JC: Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 6: 62–66, 1988
Bertolone SJ, Baum ES, Krivit W, Hammond GD: A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group. J Neuro-Oncol 7: 5–11, 1989
Tirelli V, D'Incalci M, Canetta R, et al.: Etoposide (VP-16213) in malignant brain tumors: a phase II study. J Clin Oncol 2: 432–437, 1984
Durand RE, Goldie JH: Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 71: 673–679, 1987
Crist WM, Raney RB, Rageb A, et al.: Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas. Med Pediatr Oncol 15: 51–57, 1987
Kovner EH, Kellie SJ, Horowitz ME, et al.: Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: A phase II study. J Clin Oncol 8: 330–336, 1990
Bergerat JP, Drewinko B, Corry P, et al.: Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-β-D-arabi-nofuranosyl cytosine. Cancer Res 41: 25–30, 1981
Stewart DJ, Richard MT, Benoit B, et al.: Cisplatin plus cytosine arabinoside in adults with malignant gliomas. J Neuro-Oncol 2: 29–34, 1984
Strauss LC, Killmond T, Maria BL, Carson B, Wharam M: Primary chemotherapy with cisplatin and VP-16 in children under 36 months old with brain tumors. Proc Am Soc Clin Oncol 5: 84, 1984 (abstr)
Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. JASA 53: 457–481, 1958
Edwards MS, Levin VA, Wilson CB: Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64: 1179–1205, 1980
Friedman HS, Colvin OM, Skapek SX, et al.: Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48: 4189–4195, 1988
Diez B, Monges J, Muriel FS: Evaluation of cisplatin in children. Cancer Treat. Rep. 69: 911–913, 1985
Granowetter L, Rosenstock JG, Packer RJ: Enhanced cisplatinum neurotoxicity in pediatric patients with brain tumors. J Neuro-Oncol 1: 293–297, 1983
Roelofs RI, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938, 1984
Powell BL, Capizzi RL, Lyerly ES, Cooper MR: Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin and asparaginase consolidation for acute non-lymphocytic leukemia. J Clin Oncol 4: 95–97, 1986
Russel JA, Powdes RL: Neuropathy due to cytosine arabinoside. Br Med J 4: 652–653, 1974
Falkson G, van Dyk JJ, van Eden EB, et al.: A clinical trial of the oral form of 4′-dimethyl-epipodophyllotoxin-β-D-ethylidene glucoside (NSC-141540) (VP-16–213). Cancer 35: 1141–1144, 1975
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corden, B.J., Strauss, L.C., Killmond, T. et al. Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors. J Neuro-Oncol 11, 57–63 (1991). https://doi.org/10.1007/BF00166998
Issue Date:
DOI: https://doi.org/10.1007/BF00166998